Modified or Altered Cancer Drugs can be used for the Treatment of Alzheimer's Disease
Alzheimer's disease (AD) is an irreversible, progressive brain disorder that gradually devastates memory and thinking skills, and in the end the capacity to do the simplest tasks. It is most widely recognized type of neurodegenerative dementia, influencing around 30 million individuals around the world. In its initial stages, memory misfortune is gentle, however with late-stage Alzheimer's, people lose the capacity to bear on a discussion and react to their surroundings. Alzheimer's is the sixth driving reason for death in the United States. In spite of late advances in comprehension its atomic pathology, there are no mechanism based medications as of now that are accessible to stop the movement of AD. Since amyloid-β-peptide (Aβ), an essential part of feeble plaques, is thought to be a focal pathogenic culprit, a few sickness adjusting treatments are being created, including inhibitors of Aβ-delivering proteases and immunotherapies with hostile to Aβ antibodies. Drug repositioning or repurposing is viewed as an integral and sensible way to deal with and recognize new drug candidates for AD. This critique will talk about the clinical significance of an appealing hopeful compound and points of view in regards to the conceivable repositioning of oncology medications for the treatment of AD.